FOCUS is truly intended to provide continuing medication education for practitioners that will have an impact on their practice by presenting state-of-the-art, evidence-based medicine. This issue of FOCUS is of particular relevance to psychiatrists because it provides an update on treatment-refractory psychiatric disorders including major depression, anxiety disorders, and schizophrenia. Many patients with psychiatric disorders are treated by nonpsychiatrists including family physicians, general practitioners, and obstetricians/gynecologists. This situation is unavoidable because there are simply too few psychiatrists to treat the large numbers of patients who have these major psychiatric illnesses. Therefore, as psychiatrists, we are referred the substantial numbers of patients with mood and anxiety disorders that do not respond to monotherapy with commonly prescribed psychopharmacological agents such as selective serotonin reuptake inhibitors. In this issue of FOCUS, we provide overviews of the management of treatment-refractory depression, schizophrenia, and major anxiety disorders. In addition, we provide a look into the future by reviewing the emerging field of personalized medicine in psychiatry, which has the goal of reducing treatment failures in patients with these disorders by matching individual patients with the therapies most likely to successfully treat their symptoms, both psychopharmacologically and psychotherapeutically. As with all issues of FOCUS,
From the Guest Editor
Abstract
FOCUS is truly intended to provide continuing medication education for practitioners that will have an impact on their practice by presenting state-of-the-art, evidence-based medicine. This issue of FOCUS is of particular relevance to psychiatrists because it provides an update on treatment-refractory psychiatric disorders including major depression, anxiety disorders, and schizophrenia. Many patients with psychiatric disorders are treated by nonpsychiatrists including family physicians, general practitioners, and obstetricians/gynecologists. This situation is unavoidable because there are simply too few psychiatrists to treat the large numbers of patients who have these major psychiatric illnesses. Therefore, as psychiatrists, we are referred the substantial numbers of patients with mood and anxiety disorders that do not respond to monotherapy with commonly prescribed psychopharmacological agents such as selective serotonin reuptake inhibitors. In this issue of FOCUS, we provide overviews of the management of treatment-refractory depression, schizophrenia, and major anxiety disorders. In addition, we provide a look into the future by reviewing the emerging field of personalized medicine in psychiatry, which has the goal of reducing treatment failures in patients with these disorders by matching individual patients with the therapies most likely to successfully treat their symptoms, both psychopharmacologically and psychotherapeutically. As with all issues of FOCUS,
Loading next page...
If you're having problem loading pages
Try our single-page mode to load one page at a time
Preview Only. This article cannot be rented because we do not currently have permission from the publisher.
/lp/american-psychiatric-publishing-inc-journal/from-the-guest-editor-1jK8hu2fQ9
Welcome to DeepDyve! Rent Premier Research Articles and Save Up to 90%
Preview Only
From the Guest Editor
Nemeroff, Charles B.
Follow FOCUS: The Journal of Lifelong Learning in Psychiatry
, Volume 8 (4): 473
American Psychiatric Publishing, Inc (Journal) – Oct 1, 2010
More Info
More Like This Article
View All dataSource[]=actageo&dataSource[]=aspet&dataSource[]=aaos&dataSource[]=aacc&dataSource[]=aacr&dataSource[]=aea&dataSource[]=aip&dataSource[]=ajnr&dataSource[]=ams&dataSource[]=aps_physical&dataSource[]=appi_book&dataSource[]=appi_journal&dataSource[]=apha&dataSource[]=asip&dataSource[]=asm&dataSource[]=asn&dataSource[]=aspb&dataSource[]=avs&dataSource[]=annual_reviews&dataSource[]=arxiv&dataSource[]=acm&dataSource[]=berghahn&dataSource[]=cabi&dataSource[]=clinical_trials&dataSource[]=dailymed&dataSource[]=degruyter&dataSource[]=du_press&dataSource[]=esa&dataSource[]=eu_press&dataSource[]=elsevier&dataSource[]=emerald&dataSource[]=ejtr&dataSource[]=emea&dataSource[]=epo&dataSource[]=faseb&dataSource[]=gsa&dataSource[]=health_affairs&dataSource[]=hindawi&dataSource[]=imanager&dataSource[]=imedpub&dataSource[]=informa_healthcare&dataSource[]=informs&dataSource[]=iop&dataSource[]=iucr&dataSource[]=iospress&dataSource[]=jbjs&dataSource[]=leftcoast&dataSource[]=lu_press&dataSource[]=mesharpe&dataSource[]=mary_ann_liebert&dataSource[]=medline&dataSource[]=mit_press&dataSource[]=nature&dataSource[]=oxford&dataSource[]=pier_professional&dataSource[]=pnas&dataSource[]=portlandpress&dataSource[]=psyc_articles&dataSource[]=psyc_books&dataSource[]=psyc_critiques&dataSource[]=plos_journal&dataSource[]=pubmed_central&dataSource[]=rsna&dataSource[]=rockefeller&dataSource[]=rcn&dataSource[]=ria&dataSource[]=rsc&dataSource[]=sage&dataSource[]=spie&dataSource[]=springer_journal&dataSource[]=springer&dataSource[]=taylor_francis&dataSource[]=aps&dataSource[]=the_scientist&dataSource[]=uc_press&dataSource[]=uspto_abstract&dataSource[]=wiley&dataSource[]=pct
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
